Anne Auperin
Villejuif, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Postoperative nivolumab in high-risk head and neck cancer - Authors' reply.
Journal: Lancet (London, England)
Published: July 16, 2026
Author Reply.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: May 06, 2026
Impact of HPV status on the occurrence of osteoradionecrosis in patients with oropharyngeal carcinoma treated with definitive radiotherapy or chemoradiotherapy.
Journal: Journal of stomatology, oral and maxillofacial surgery
Published: April 10, 2026
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 18, 2026
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 22, 2026
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: June 23, 2025
Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial.
Journal: The lancet. Healthy longevity
Published: May 19, 2025
Intensification or de-escalation? What is the standard treatment for human papillomavirus-related oropharyngeal cancers in 2025?
Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Published: May 16, 2025
Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: February 10, 2025
A microsimulation model based on healthcare pathways to estimate the impact of COVID-19 pandemic-induced delays on breast cancer mortality.
Journal: Journal of clinical epidemiology
Published: December 16, 2024
Last Updated: 09/26/2026